Finbiosoft
Finbiosoft, specialising in clinical diagnostics, was sold in spring 2024 to the French information-management company BYG4lab, with backing from the Growth Buyout fund Keensight Capital. BYG4lab highlighted that the acquisition strengthens its technological capabilities and opens up new opportunities, particularly in Europe and the United States.
Exit type
Acquisition, 3/2024
Purchase price
Not made public
Investment multiple at exit
0.8x
Investment’s IRR
-4.7%
Returns for Springvest
€0.35 million (before taxes)
Springvest’s funding rounds
8/2015, 1/2018
Valuation after second round
Approx. €9 million
Total funding arranged by Springvest
€3.09 million
